AI English summary of an SEC filing — figures as filed
Quest Diagnostics DGXQuest Diagnostics said net revenues for the 3 months ended March 31, 2026 increased 9.2% compared to the prior year period and DIS revenues increased 9.4%. DIS volume increased 10.9% and revenue per requisition decreased 1.3%.
Key points
AI summaryQuest Diagnostics said net revenues for the 3 months ended March 31, 2026 increased 9.2% compared to the prior year period and DIS revenues increased 9.4%. DIS volume increased 10.9% and revenue per requisition decreased 1.3%.
The company said approximately 7% of the organic DIS volume growth of 10.8% was attributable to its new relationship with Corewell Health to provide Collaborative Lab Solutions and expansion of laboratory testing at dialysis clinics owned by Fresenius Medical Care. Excluding these relationships, organic volume increased 3.8%.
Quest Diagnostics said net cash provided by operating activities for the 3 months ended March 31, 2026 was $278 million, a decrease of $36 million compared to $314 million in the prior year period. Net cash used in investing activities was $152 million and net cash used in financing activities was $152 million.
The company said it completed its transaction with Corewell Health to form a new entity to perform laboratory testing in Michigan on January 2026. The company holds 51% equity ownership and Corewell Health holds 49%, and the company is consolidating the entity in its consolidated financial statements.
Key figures
Quarter ended March 31, 2026
- Revenue
- $2.9B
- Operating income
- $399M
- Net income
- $252M
- EPS
- $2.24
- Operating cash flow
- $278M
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Net revenues, DIS revenues, volume and revenue per requisition as of Q1 2026
Quest Diagnostics said net revenues for the 3 months ended March 31, 2026 increased 9.2% compared to the prior year period and DIS revenues increased 9.4%. DIS volume increased 10.9% and revenue per requisition decreased 1.3%.
Source · Based on the MD&A text of the filing
DIS volume growth from Corewell Health and Fresenius relationships
The company said approximately 7% of the organic DIS volume growth of 10.8% was attributable to its new relationship with Corewell Health to provide Collaborative Lab Solutions and expansion of laboratory testing at dialysis clinics owned by Fresenius Medical Care. Excluding these relationships, organic volume increased 3.8%.
Source · Based on the MD&A text of the filing
Operating, investing and financing cash flows as of Q1 2026
Quest Diagnostics said net cash provided by operating activities for the 3 months ended March 31, 2026 was $278 million, a decrease of $36 million compared to $314 million in the prior year period. Net cash used in investing activities was $152 million and net cash used in financing activities was $152 million.
Source · Based on the MD&A text of the filing
Corewell Health new entity transaction completion and equity structure
The company said it completed its transaction with Corewell Health to form a new entity to perform laboratory testing in Michigan on January 2026. The company holds 51% equity ownership and Corewell Health holds 49%, and the company is consolidating the entity in its consolidated financial statements.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…